Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006.
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X1, Motea EA1, Moore ZR1, Yao J1, Dong Y1, Chakrabarti G1, Kilgore JA2, Silvers MA1, Patidar PL1, Cholka A1, Fattah F1, Cha Y3, Anderson GG4, Kusko R3, Peyton M5, Yan J6, Xie XJ6, Sarode V7, Williams NS2, Minna JD5, Beg M5, Gerber DE5, Bey EA8, Boothman DA9.